loading...| Preferred Name |
nadolol |
|
| Synonyms |
Corgard |
|
| Definitions |
A non-selective beta-adrenergic antagonist with antihypertensive and antiarrhythmic activities. Nadolol competitively blocks beta-1 adrenergic receptors located in the heart and vascular smooth muscle, inhibiting the activities of the catecholamines epinephrine and norepinephrine and producing negative inotropic and chronotropic effects. This agent exhibits antiarrhythmic activity via the impairment of atrioventricular (AV) node conduction and a corresponding reduction in sinus rate. In the kidney, inhibition of the beta-2 receptor within the juxtaglomerular apparatus results in the inhibition of renin production and a subsequent reduction in angiotensin II and aldosterone levels, thus inhibiting angiotensin II-dependent vasoconstriction and aldosterone-dependent water retention. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29280" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29280" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000659002 |
|
| altLabel |
Corgard |
|
| CAS Registry |
42200-33-9 |
|
| cui |
C0027302 C0591292 |
|
| DATE FIRST PUBLISHED |
2009-11-05 |
|
| Date last modified |
2009-11-09 |
|
| definition |
A non-selective beta-adrenergic antagonist with antihypertensive and antiarrhythmic activities. Nadolol competitively blocks beta-1 adrenergic receptors located in the heart and vascular smooth muscle, inhibiting the activities of the catecholamines epinephrine and norepinephrine and producing negative inotropic and chronotropic effects. This agent exhibits antiarrhythmic activity via the impairment of atrioventricular (AV) node conduction and a corresponding reduction in sinus rate. In the kidney, inhibition of the beta-2 receptor within the juxtaglomerular apparatus results in the inhibition of renin production and a subsequent reduction in angiotensin II and aldosterone levels, thus inhibiting angiotensin II-dependent vasoconstriction and aldosterone-dependent water retention. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29280" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29280" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C29280 |
|
| notation |
CDR0000659002 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
nadolol |
|
| tui |
T109 T121 |